REDUCED FOLATE IS REQUIRED to provide single-carbon units for the synthesis of purines and thymidine, for the interconversion of serine and glycine, for the degradation of histidine and glycine, and for the methylation of homocysteine to regenerate methionine ( Fig. 1) (2, 3, 8, 28, 34) . Figure 1 shows the structures and interconversions of bioactive reduced folate derivatives. Whereas 5-methyltetrahydrofolate (5-CH 3 -H 4 PteGlu) is the principal folate in plasma (8, 38) , we found four reduced folate derivatives in rat bile, tetrahydrofolate (H 4 PteGlu), 5-CH 3 -H 4 PteGlu, 5,10-methylenetetrahydrofolate (5,10-CH 2 -H 4 PteGlu), and 10-formyltetrahydrofolate (10-HCO-H 4 PteGlu), as shown in Fig. 1 (29, 30, 31) . Because bile drainage causes a rapid reduction in plasma folate concentration (30, 32) , enterohepatic circulation plays an important role in folate homeostasis, i.e., maintenance of plasma folate concentrations. We (30) and Horne (11) proposed a physiological role for enterohepatic circulation of reduced folate derivatives as the source for the reutilization of folate, because 1) enteric infusion of 5-CH 3 -H 4 PteGlu and nonmethylated reduced folate derivatives maintained the plasma concentration of 5-CH 3 -H 4 PteGlu in rats with bile drainage (30) , and 2) intravenous administration of folic acid (PteGlu), which has been postulated as a waste product (10, 32) , elevated the biliary excretion of all reduced folate derivatives (30) .
The hepatic elimination of compounds from the circulating blood consists of two steps: transport across both the basolateral and the bile canalicular membrane. The hepatic uptake of 5-CH 3 -H 4 PteGlu has been characterized in vitro using isolated hepatocytes (11) and basolateral membrane vesicles (12) in rats. Hepatic uptake of 5-CH 3 -H 4 PteGlu does not depend on the sodium concentration but depends on the proton concentration in the medium, since an inward proton gradient stimulated the uptake of 3 H-labeled 5-CH 3 -H 4 PteGlu into isolated hepatocytes and basolateral membrane vesicles (11, 12) , which is a common characteristic with the uptake of this substrate in the small intestine (21, 27) . In spite of its structural similarity to 5-CH 3 -H 4 PteGlu, the hepatic uptake of methotrexate, an inhibitor for dihydrofolate reductase, showed different characteristics: 1) pH dependence was biphasic and showed maximal uptake at pH 7.0 (11), and 2) its uptake into isolated hepatocytes showed sodium dependency (11) .
The mechanism for the transport of reduced folate derivatives across the bile canalicular membrane has not been clarified yet. Strum and Liem (35) reported that 5-CH 3 -H 4 PteGlu in bile was 14-to 16-fold larger than that in liver parenchyma, suggesting the presence of an active transporter on the bile canalicular membrane. Three kinds of primary active transporters for organic compounds have been identified on this membrane: a transporter for bile acids, P-glycoprotein, and canalicular multispecific organic anion transporter (cMOAT) (18, 20, 25, 42) . cMOAT has been identified as a primary active transporter for organic anions, and its cDNA has been cloned recently (5, 14, 15, 17, 26) . In the Eisai hyperbilirubinemic rats (EHBR) and TR Ϫ rats, which are derived from Sprague-Dawley rats (SDR) and Wistar rats, respectively, cMOAT is hereditarily deficient, while other primary active transporters are maintained. Using these animals, we and others (18, 20, 25, 42) have demonstrated that substrates for cMOAT include glutathione conjugates, glucuronides, sulfates of several bile acids, and some organic anions without conjugation. Because 1) we demonstrated previously (22) through examining the ATP-dependent uptake into canalicular membrane vesicles (CMV) prepared from SDR and EHBR that methotrexate is extruded via cMOAT, and 2) reduced folate derivatives have an anionic moiety, i.e., two carboxyl residues in their glutamic residue, which is a common characteristic among substrates for cMOAT (18, 20, 25, 42) , we hypothesized that cMOAT may be responsible for the hepatobiliary transport of reduced folate derivatives and may play a role in folate homeostasis. In the present study, we examined this hypothesis in vivo and in vitro.
MATERIALS AND METHODS
Materials. PteGlu, (6R,S)-5-CH 3 -H 4 PteGlu calcium salt, (6R,S)-5,10-CH 2 -H 4 PteGlu magnesium salt, and (6R,S)-H 4 PteGlu trihydrochloride were purchased from Dr. B. Schircks Laboratories (Jona, Switzerland). Sodium ascorbate and paraformaldehyde were purchased from Wako Pure Chemicals (Osaka, Japan). All folate derivatives were dissolved in 0.2% sodium ascorbate solution except for 5,10-CH 2 -H 4 PteGlu, which was dissolved in 0.2% sodium ascorbate solution containing 3 ϫ 10 Ϫ3 % paraformaldehyde. They were stored at Ϫ80°C. Louis, MO) as described previously (19) , and the purity was checked by TLC. ATP, creatine phosphate, and creatine phosphokinase were purchased from Sigma Chemical. All chemicals and reagents were of analytic grade.
Animals and sampling of biological fluids. SDR (male, 6 wk; Nihon Ikagaku, Tokyo, Japan) and EHBR (male, 6 wk; SLC Japan, Shizuoka, Japan) were used throughout the experiments. The animals were anesthetized with an intraperitoneal dose of urethan (1 g/kg body wt) throughout the experimental period. Blood was collected in test tubes containing sodium ascorbate (2 mg/ml plasma) as an antioxidant via a polyethylene catheter (PE-50) inserted into the femoral artery. After plasma separation, it was stored at Ϫ20°C until analysis. Bile specimens were collected into tubes placed on ice via a polyethylene catheter (PE-10) inserted into the bile duct. In the present study, sodium ascorbate (0.8%) was added to the bile specimens to prevent the oxidation of reduced folate derivatives (30) . The volume of the sodium ascorbate was adjusted to provide a final concentration of 0.4%, taking into account the bile flow rate (ϳ10 µl · min Ϫ1 · rat Ϫ1 ); e.g., for the collection at 30-min intervals, the bile specimens were collected in the tube containing 300 µl of the sodium citrate solution. After measuring the volume, we stored the bile samples at Ϫ20°C until analysis. Plasma and bile folate levels were determined using HPLC with electrochemical detection as reported previously (29, 31) .
Intravenous administration of PteGlu. Rats were kept for 1 h under anesthesia with bile drainage before intravenous administration of oxidized folate (PteGlu) (1 mg/kg). Endogenous biliary excretion of reduced folate derivatives was determined before administration of PteGlu. Blood and bile specimens were collected as described previously for 4 h at 1-h and 30-min intervals, respectively.
Preparation of CMV. CMV were prepared from male SDR and EHBR using the slightly modified method of Meier and Boyer (23) . After suspension of CMV in 10 mM Tris · HCl buffer (pH 7.4) containing 250 mM sucrose, CMV were frozen in liquid N 2 and stored at Ϫ100°C until required. The transport activity of CMV used in this study was also checked by measuring the ATP-dependent uptake of [ 3 H]DNP-SG (1 µM) for a 2-min incubation period at 37°C.
Uptake of 5-CH 3 -H 4 PteGlu into CMV.
The transport study was performed using the rapid filtration technique described in a previous report (13) . Fifteen microliters of transport medium (10 mM Tris, 250 mM sucrose, and 10 mM MgCl 2 , pH 7.4) containing radiolabeled compounds, ATP-regenerating system (10 mM creatine phosphate and 100 µg/ml creatine phosphokinase), 5 mM ATP (or 5 mM AMP), and 0.5% sodium ascorbate as an antioxidant with or without unlabeled substrate were preincubated at 37°C for 3 min and then rapidly mixed with 5 µl CMV suspension containing 10 µg protein.
The transport reaction was stopped by the addition of 1 ml ice-cold buffer containing 250 mM sucrose, 100 mM NaCl, and 10 mM Tris · HCl (pH 7.4). The stopped reaction mixture was filtered through a 0.45-µm HAWP filter (Millipore, Bedford, MA) and washed twice with 5 ml of stop solution. Radioactivity retained on the filter was determined using a liquid scintillation counter (LSC-3500, Aloka, Tokyo, Japan). The uptake was normalized with respect to both the amount of CMV and the medium concentration of ligand. The saturation study for the uptake of 5-CH 3 Estimation of kinetic parameters. The kinetic parameters for the uptake of 5-CH 3 -H 4 PteGlu by CMV were estimated from the following equation
where V 0 is the initial uptake rate of the substrate (in pmol · min Ϫ1 · mg protein Ϫ1 ), S is the substrate concentration in the medium (in µM), K m is the Michaelis-Menten constant (in µM), V max is the maximum uptake rate (in pmol · min Ϫ1 ·mg protein Ϫ1 ), and P diffusion is clearance for the nonspecific uptake (in µl · min Ϫ1 · mg protein Ϫ1 ). Equation 1 was fitted to the uptake data sets by an iterative nonlinear least-squares method using a MULTI program (41) to obtain estimates of the kinetic parameters. The input data were weighted as the reciprocal of the observed values, and the DampingGauss-Newton method algorithm was used for fitting. The fitted line was converted to the V 0 /S vs. http://ajpgi.physiology.org/ competitive inhibition to obtain the K i for the inhibitor.
RESULTS
Endogenous levels of reduced folate derivatives in rat plasma and bile. Figure 2 shows the plasma concentrations and biliary excretion time profiles of reduced folate derivatives in SDR and EHBR with bile drainage. 5-CH 3 -H 4 PteGlu and H 4 PteGlu were detected in SDR and EHBR plasma (Fig. 2A) . The endogenous plasma concentration of 5-CH 3 -H 4 PteGlu in EHBR was 58% of that in SDR, whereas the H 4 PteGlu concentration was similar for EHBR and SDR. Four hours after the initiation of bile drainage, plasma folate concentrations in SDR were reduced to 69% and 29% of the initial 5-CH 3 -H 4 PteGlu and H 4 PteGlu concentrations, respectively, whereas concentrations in EHBR were unaffected ( Fig. 2A) .
The biliary excretion of reduced folate derivatives in SDR and EHBR was constant for at least up to 4 h (Fig.  2, B and C) . The endogenous biliary excretion rate of H 4 PteGlu, 5-CH 3 -H 4 PteGlu, and 5,10-CH 2 -H 4 PteGlu in EHBR was 8.2%, 1.9%, and 5.5% of that in SDR (Table 1). 10-Formyltetrahydrofolate (10-HCO-H 4 PteGlu) was not detected in EHBR bile.
Alteration of folate concentration in plasma and bile after exogenous administration of PteGlu. When PteGlu (1 mg/kg) was given intravenously, the maximal plasma concentration of 5-CH 3 -H 4 PteGlu and H 4 PteGlu increased 2-and 10-fold, respectively, relative to the initial value in SDR and EHBR (Fig. 3A) . Increased plasma concentrations returned to endogenous levels at 4 h after administration in SDR. Although the maximal concentration was almost the same for SDR and EHBR, a prolonged elimination half-life was observed in EHBR.
Intravenous administration of PteGlu increased the biliary excretion rate of all reduced folate derivatives four-to sixfold maximally, relative to the endogenous excretion rate in SDR (Fig. 3B) . Although the increase in plasma concentration in EHBR was similar to that in SDR (Fig. 3A) , a minimal increase in biliary excretion rate was observed in EHBR (Fig. 3C) . Figure 4 shows the time profiles for the uptake of 3 H-labeled 5-CH 3 -H 4 PteGlu (0.08 µM) into CMV prepared from SDR and EHBR in the presence of 5 mM ATP or AMP. ATP stimulated the uptake into CMV prepared from SDR but did not stimulate the uptake into CMV prepared from EHBR. The ATP-dependent uptake was linear up to 2 min and did not show any overshoot phenomenon even at 30 min (data not shown).
Uptake of 3 H-labeled 5-CH 3 -H 4 PteGlu into CMV.

Saturation of ATP-dependent uptake of 3 H-labeled 5-CH 3 -H 4 PteGlu into CMV.
To obtain the kinetic parameters (K m , V max ), we examined the concentration dependence of the ATP-dependent uptake of 3 H-labeled 5-CH 3 -H 4 PteGlu into CMV, and the data are shown as an Eadie-Hofstee plot (Fig. 5) . Nonlinear regression analysis revealed that the uptake can be described by a saturable and a nonsaturable component and yielded a K m of 125 Ϯ 16 µM, V max of 272 Ϯ 19 pmol · min Ϫ1 ·mg protein Ϫ1 , and a clearance for the nonsaturable component of 0.20 Ϯ 0.02 µl · min Ϫ1 · mg protein Ϫ1 (Fig. 5) .
Inhibitory effect of reduced folate derivatives on uptake of [ 3 H]DNP-SG and vice versa.
The inhibitory effect of reduced folate derivatives on the uptake of [ 3 H]DNP-SG (1 µM) and that of DNP-SG on the uptake of 3 H-labeled 5-CH 3 -H 4 PteGlu (1 µM) into CMV was examined (Fig. 6 ). As shown in Table 2 (Fig. 6) .
DISCUSSION
In the present study, we examined the biliary excretion mechanism of reduced folate derivatives in vivo and in vitro using normal rats (SDR) and mutant rats (EHBR) whose cMOAT is hereditarily deficient.
Continuous bile drainage caused a reduction in the endogenous plasma concentration of 5-CH 3 -H 4 PteGlu and H 4 PteGlu in SDR ( Fig. 2A) , which is consistent with our previous findings (30) . The biliary excretion was not affected as much by bile drainage, in spite of the reduction in plasma folate concentration (Fig. 2B) . Because the major form (Ͼ90%) of folates in the bile is 5-CH 3 -H 4 PteGlu after its intravenous administration in normal rats (30) , the source for endogenous reduced folates in the bile may not be 5-CH 3 -H 4 PteGlu in the http://ajpgi.physiology.org/ blood. Therefore, another source(s) must be responsible for maintaining the folate levels in the bile; indeed, two possible sources are postulated. Because most of the folates in the liver exist in polyglutamate form (4, 6) , their conversion to monoglutamate form may maintain their biliary excretion. The salvage pathway of PteGlu in the blood may be another source for the reduced folate derivatives in the bile (10, 32) , since reduced folate concentrations in the plasma and bile were increased after PteGlu administration (Fig. 3, A and B) . To elaborate, folates, including PteGlu, are released from dying cells such as senescent erythrocytes, and this process is known as the salvage pathway (7, 10, 16, 33) .
In contrast to SDR, the biliary excretion of reduced folate derivatives in EHBR was only 3% of that in SDR (Table 1) . Thus the minimal contribution of biliary excretion to the overall elimination of folates from the plasma in EHBR may explain why bile drainage had no effect on plasma concentration (Fig. 2A) . In addition, intravenous administration of PteGlu failed to increase the biliary excretion of reduced folate derivatives in EHBR (Fig. 3C) , although plasma concentration increased as observed in SDR (Fig. 3A) . This holds for endogenous folates as well; i.e., the endogenous concentration of folate derivatives in the plasma was comparable between SDR and EHBR ( Fig. 2A) , though their levels in the bile were greatly reduced in EHBR. These observations suggest that plasma folate concentration in EHBR is maintained in a different manner from that of SDR. The prolonged elimination half-life in EHBR plasma after administration of PteGlu indicated the lower total body clearances of 5-CH 3 -H 4 PteGlu and H 4 PteGlu compared with those in SDR, which results from the diminishment of biliary excretion (Fig. 3C) . Because enterohepatic circulation supplies 5-CH 3 -H 4 PteGlu to blood (30) in SDR as well as the salvation pathway described above, it is plausible that the folate supply into blood may be decreased in EHBR compared with SDR. Thus both the lower supply into blood and the lower plasma clearance of folates may compensate each other, which results in the minimum change in endogenous folate concentration in plasma.
The intestinal transport of folates has not been investigated in cMOAT-deficient rats. De Vries et al. (9) perfused the small intestine and found no difference in the transport of ␣-naphthyl ␤-D-glucuronide across the brush-border and basolateral membranes between normal and cMOAT-deficient rats. Their results suggest that the contribution of cMOAT to the transport of its substrates in the small intestine is minimal, although a Northern blot indicated the expression of this transporter (15) . The expression of transporters responsible for the intestinal uptake of folate has not been examined in cMOAT-deficient rats.
To demonstrate directly the contribution of cMOAT to the biliary excretion of reduced folate derivatives, we examined the uptake of 3 H-labeled 5-CH 3 -H 4 PteGlu into CMV prepared from SDR and EHBR (Fig. 4) . As reported previously from our laboratory (36) , the CMV prepared from SDR exhibited ATP-dependent uptake for DNP-SG and TCA, while ATP-dependent uptake of DNP-SG by CMV prepared from EHBR was diminished to approximately one-thirtieth relative to that by CMV http://ajpgi.physiology.org/ from SDR. ATP stimulated the uptake of 3 H-labeled 5-CH 3 -H 4 PteGlu into the CMV from SDR, while this ATP-dependent uptake was diminished in EHBR (Fig. 4) . Overshoot phenomena, however, was not observed in ATP-dependent uptake of 3 H-labeled 5-CH 3 -H 4 PteGlu into CMV from SDR. Because overshoot phenomena are caused by ATP consumption and the subsequent release of substrates from inside the vesicles (40) , it may be possible that low membrane permeability due to high hydrophilicity of 5-CH 3 -H 4 PteGlu may prevent its detectable release from the vesicles, even after the consumption of ATP.
Kinetic analyses revealed that K m and K i values for 5-CH 3 -H 4 PteGlu were comparable ( Table 2 ). The K i value for DNP-SG was also comparable with a K m value reported from this laboratory (18 µM) (24) ( Table 2 ). These results suggest that DNP-SG and 5-CH 3 -H 4 PteGlu share an efflux transporter on the bile canalicular membrane. We conclude that 5-CH 3 -H 4 PteGlu is a substrate for cMOAT, because, along with in vivo results, 1) DNP-SG is extruded via cMOAT on the bile canalicular membrane (24, 36, 37) and 2) ATP-dependent uptake of 5-CH 3 -H 4 PteGlu was diminished in the CMV prepared from EHBR (Fig. 4) . Organic anions with a hydrophobic group and two carboxylate groups are liable to higher affinity substrates for cMOAT than compounds without such characteristics. Also, the glutathione moiety is important for maximum affinity for cMOAT. The K m values for the cMOAT of leukotriene C 4 (LTC 4 ), glutathione disulfide, ␤-estradiol 17-(␤-Dglucuronide), methotrexate, and 5-CH 3 -H 4 PteGlu were 0.25, 400, 75, 295, and 126 µM, respectively (1, 13, 22, 39) . The K i values for cMOAT of 5,10-CH 2 -H 4 PteGlu and H 4 PteGlu are 269 and 358 µM. Although both LTC 4 and glutathione disulfide have a glutathione moiety, there was a 1,600-fold difference in their K m values. This seems to be due to the fact that LTC 4 has a hydrophobic domain in its structure, while glutathione disulfide does not. Reduced folate derivatives are endogenous substrates for cMOAT with comparable K m values with ␤-estradiol 17-(␤-D-glucuronide) and methotrexate. However, their affinity for cMOAT is 500-to 1,400-fold lower than that of LTC 4 , which has a glutathione moiety in its structure.
Cumulative in vivo and in vitro studies revealed the endogenous substrates for cMOAT, which include glucuronides [such as ␤-estradiol 17-(␤-D-glucuronide), bilirubin diglucuronide, and the glucuronides of several bile acids], glutathione conjugates (such as oxidized glutathione and LTC 4 ), and sulfates of several bile acids (18, 20, 25, 42) . The excretion into bile mediated by cMOAT is one of the inactivation/detoxification pathways for these endogenous substrates. Because reduced folate derivatives are substrates for cMOAT without requiring conjugation, this is the first report of an endogenous substrate for cMOAT without a glutathione, glucuronide, or sulfate moiety in its structure.
In conclusion, cMOAT is responsible for the biliary excretion of reduced folate derivatives. It is possible that this biliary excretion provides an efficient reutilization system of folate together with the uptake by small intestine and may supply reduced folate constantly to intestinal mucosa in which rapid cell division occurs and requires reduced folates as a cofactor for biosynthesis of DNA and RNA.
